Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Slight Increase in Revenues, Widening Losses for Q2

NEW YORK, Aug. 16 (GenomeWeb News) - Transgenomic reported increased revenues and widening losses for the second quarter of 2004 last week.

 

The company booked $9 million in revenues for the quarter, up from $8.5 million during the same quarter last year.

 

R&D costs decreased to $1.7 million, down from $2.4 million during the same period a year ago.

 

Transgenomic's net loss for the quarter amounted to $15.1 million, or $.52 per share, up from $4.7 million, or $.2 per share, during the second quarter a year ago. This loss included a $12 million non-cash impairment charge related to the company's nucleic acids operating segment.

 

As of June 30, Omaha, Neb.-based Transgenomic had $2.1 million in cash, cash equivalents, and short-term investments.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.